Fig. 2. Liver-mediated suppression of antitumor immunity is tumor-antigen specific and independent of tumor burden.
(A) Day 20 subcutaneous (SQ) tumor size from B6 mice that were implanted with MC38 tumor cells (5 × 105) subcutaneously alone as a control, subcutaneously and at the left kidney, subcutaneously and intra-peritoneum (I.P.), and subcutaneously and at the liver. (B) SQ tumor sizes in mice implanted with MC38 tumor cells subcutaneously, subcutaneously and at the liver, subcutaneously with irradiated (50 Gy) MC38 tumor cells (5 × 105) at the liver, and subcutaneously with MC38 tumor cell lysates (from 5 × 105 cells) at the liver. (C) SQ tumor sizes in mice implanted with MC38 tumor cells subcutaneously, subcutaneously and at the liver, subcutaneously with 5 × 105 irradiated MC38 tumors cells at the liver, and subcutaneously with 5 × 104 irradiated MC38 tumor cells at the liver. (D) SQ tumor sizes in mice implanted with MC38 tumor cells subcutaneously, subcutaneously with saline (PBS) at the liver, subcutaneously with heterologous B16F10 tumor cells (5 × 105) at the liver, and subcutaneously with homologous MC38 tumor cells at the liver. Representative whole mouse bioluminescent image of implanted MC38 tumors from each experimental group for day 20 are shown (A-D, upper row). Data are shown as mean +/− s.e.m. Asterisks indicating significance determined by unpaired t tests between groups are * p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. Representative data from one out of at least two independent experiments are shown.